Risk of Cutaneous Squamous Cell Carcinoma
Kidney transplantation is the preferred modality of renal replacement therapy for many patients with end-stage renal disease. As short-term patient and allograft survival are excellent nowadays, improvement of long-term morbidity and mortality due to malignancies have emerged as key goals. Renal transplant recipients (RTRs) have at least a 3-to 4-fold increased risk of developing cutaneous cancer after transplantation compared to the general population [1] . The most common cancer in RTRs is nonmelanoma skin cancer (NMSC). While the usual incidence ratio of cutaneous squamous cell carcinoma (cSCC):basal cell carcinoma (BCC) is 1: 4 in the immunocompetent population, this ratio is reversed in transplant recipients. The risk of developing cSCC is estimated to be 65-fold higher than for the general population [2] . Therefore, more than 36% of all transplanted and immunosuppressed patients develop at least 1 NMSC after transplantation [3, 4] . UV irradiation, type and duration of immunosuppression, as well as age at transplantation and time period after transplantation constitute the main risk factors for the development of cSCCs. Furthermore, fair skin as well as history of prior skin cancer and actinic keratoses are known to increase the risk of NMSC emergence [5, 6] but do not cover the individual risk. Therefore, all RTRs are supplied with yearly follow-up examinations. Identification of a genetic risk factor might help to estimate the individual risk and to establish an individual monitoring resulting in lower health care costs.
Epidermodysplasia verruciformis (EV) is a rare autosomal-recessive disorder leading to an increased susceptibility to persistent infections by cutaneous β-human papillomaviruses (β-HPVs) [7] . Patients with EV develop disseminated cutaneous wart-like lesions and have an increased risk of developing cSCC in sun-exposed skin areas, which is comparable to the risk of skin cancer development in RTRs. In 2002, homozygous nonsense and frameshift mutations in the TMC6/EVER1 and TMC6/ EVER2 genes have been identified in patients with EV [8] and could be confirmed in about 75% of patients. These loss-of-function mutations result in an increased susceptibility to infections by specific HPVs of the genus β, mainly HPV-5 and -8 [8] . Both TMC/EVER genes contain numerous single-nucleotide polymorphisms (SNPs), most of them leading to missense mutations. Their relevance on cancer development has been discussed recently [9] [10] [11] .
Likewise another SNP (rs1042522) in the TP53 gene (c. 215CCC>CGC; p.Pro72Arg) at codon 72 has been controversially discussed to be associated with cancer development [12] [13] [14] [15] [16] . This alteration possibly increases the susceptibility of the TP53 protein to degradation mediated by E6 of HPVs [17, 18] . An important hint for the involvement of SNP rs1042522 in NMSC development is its homozygosity in a considerable number of EV patients [19] . Furthermore, this SNP was significantly associated with NMSC development in RTRs [20] .
The objective of our pilot study was to evaluate a direct correlation of SNPs within TMC6/EVER1 and TMC8/ EVER2 as well as to prove influences of rs1042522 in TP53 on an increased risk of cSCC development in RTRs.
Materials and Methods

Study Population
The study was approved by the Ethics Committee of Basel, Switzerland (EK11/10), and informed consent was given by all participants. The procedures were in accordance with the Helsinki Declaration.
105 RTRs of Central European origin who had been transplanted and followed after transplantation at one center (University Hospital Basel, Switzerland) at least 7 years previously were included in the study; data were collected from patient records. Patients were classified according to the number of previous and current NMSCs and warts as well as type of medically induced immunosuppression, Fitzpatrick skin type and UV exposure. Patients with a history of cancer other than cSCC or BCC were not included in the study. Patients were grouped into severely affected [multiple ( ≥ 3) cSCC, group 1, n = 16], moderately affected (development of 1 or 2 cSCC or no cSCC but BCC and/or precancerous lesions, group 2, n = 64), and nonaffected patients (no cSCC, no warts, no precancerous lesions, group 3, n = 25). The anonymous control group (n = 113) included non-transplanted individuals from the general Central European population without any known increased risk of cSCC. The mean age at transplantation was 42 years (group 1), 46 years (group 2) and 40 years (group 3). The male:female ratio was 4: 1 (group 1), 1.3: 1 (group 2) and 1.4: 1 (group 3).
All patients received immunosuppressive treatment with cyclosporine, azathioprine, prednisone, rapamycin, mycophenolate mofetil and tacrolimus. In most cases, the drugs were administered in a combined therapy (e.g. cyclosporine/prednisone, azathioprine/prednisone, cyclosporine/mycophenolate mofetil, rapamycin/mycophenolate mofetil). Comparison of medication between the patients showed a comparable immunosuppressive treatment for all groups. In only 1 patient was immunosuppressive treatment stopped because of severe progression of cancers with brain invasion and skin metastasis.
DNA Preparation and SNP Analysis
Genomic DNA was extracted from peripheral blood lymphocytes following the standard salting-out procedure. PCR (Qiagen, Valencia, Calif., USA) was performed by means of primers amplifying the entire coding sequences of the TMC6 and TMC8 genes as well as exon-intron boundaries. Primer sequences were kindly imparted by G. Orth, France. In order to test our hypothesis in a pilot study, we focused on comparing genotypes of RTRs, who were severely affected by multiple cSCCs and precancerous lesions (group 1) and patients not affected by cSCC, precancerous lesions or warts (group 3). In a first attempt to detect SNPs influencing cSCC development in RTRs, purified PCR products (NucleoSpin Extract II, Macherey-Nagel) of individuals in group 1 (n = 5) and group 3 (n = 4) were subjected to bidirectional sequencing using the Big-Dye terminator kit (v 3.1) and ABI Prism 377 sequencer (Applied Biosystems, Foster City, Calif., USA). Distinguished nonsynonymous SNPs or SNPs possibly affecting the splice sites were screened in all RTR patients of both groups. Screening of TMC/ EVER SNPs was carried out either by the TaqMan ® SNP Genotyping Assay (Applied Biosystems, Carlsbad, Calif., USA) according to the manufacturer's instruction or by restriction fragment length polymorphism analysis (RFLP). For RFLP, PCR products spanning the region of interest were digested with site-specific enzyme (New England Biolabs) according to the manufacturer's instructions ( table 1 ; primer sequences are available on request). TP53 SNP rs1042522 was characterized by RFLP after digestion of the PCR product with Fau I (New England Biolabs).
Statistical Analysis
Data analysis of the genotypes was assessed using the statistical program R (http://www.r-project.org/). In case of the presence of 3 different genotypes for a specific SNP, the significance was calculated by the Cochran-Armitage test and logistic regression. In case of only 2 different genotypes for a specific SNP, the Fisher test was applied. All significances were calculated using the additive model.
Results
In our study collective, 16 patients (15.2%) were severely affected by cSCC (group 1). Patients in this group (n = 10/62.5%) suffered from multiple cSCCs as well as from multiple precancerous lesions, which developed between 3 and 24 years after transplantation (median age at first cSCC 58 ± 14 years). Four patients (25%) were afflicted with 4-8 cSCCs in addition to precancerous lesions, and 2 patients (12.5%) developed 3 cSCCs combined with multiple precancerous lesions at an early time point after transplantation (6 and 9 years). Group 2 consisted of 64 patients (61.0%), who developed only 1, 2 or no cSCC but 1 precancerous lesion or BCC at least. Group 3 consisted of 25 patients (23.8%) who have never developed cSCC, BCC or precancerous lesions (median age at examination 54 ± 12 years).
Genotypes in both TMC/EVER genes were investigated in patient groups, which differed most strongly regarding development of cSCC (groups 1 and 3 SNPs revealed no significant difference, neither between group 1 and group 3 nor compared to the control group ( table 2 ) . Notably, no significant discrepancy was found for rs7208422 [ TMC8 c.917A>T, p.(Asn306Ile); p = 0.15] among the investigated groups. The novel SNP in TMC8 (c.1766G>A) showed a minor allele frequency (MAF) of A = 0.020/1 in all RTR patients. Overall, the MAF in both RTR groups as well as in the control group ranged from 0.014 (rs16970849) to 0.049 (rs7208422). The allele frequency of rs1042522 in TP53 did not significantly differ between the RTR groups (group 1 MAF: C = 0.219/7, group 3 MAF: C = 0.220/11) or in comparison to the control group (MAF: C = 0.258/51; table 1 ).
Discussion
Influences of SNPs on cancer development have been debated since their discovery [21, 22] . TMC6/EVER1 and TMC8/EVER2 are known to be involved in the development of EV. Homozygous deleterious alterations in either gene promote the susceptibility of the mutant carrier to β-HPV and cSCC [23] . β-HPVs are discussed to have an impact on cSCC development in RTRs [24] [25] [26] , implicating that SNPs in TMC6/EVER1 and TMC8/EVER2 might constitute a risk factor for the different susceptibilities of RTRs to cSCC. To test this hypothesis we examined RTRs starting from 7 to 42 years after transplantation for SNPs in both TMC/EVER genes. Number of cSCCs, age of onset and sex ratio of our study cohort are comparable to previously published data [2, 6, 27, 28] .
Our investigation of TMC6/EVER1 and TMC8/EVER2 in RTRs revealed 26 different SNPs causing missense or silent mutations or being located in the introns near the exon-intron boundaries. We compared the frequency of these SNPs between RTRs with severe cSCC affection and RTRs without any skin cancer. Surprisingly, statistical analyses by the Cochran-Armitage test or Fisher test could not identify any SNP significantly associated with an increased risk of the development of cSCC in RTR. Neither risk analysis by logistic regression revealed any statistical significance.
Influences of SNPs on both TMC/EVER genes on cSCC development have been investigated recently. First studies examined the correlation of an SNP in TMC8/ EVER2 (rs7208422), which is located in exon 8 of TMC8 and leads to a missense mutation [c.917A>T, p. (Ile306Asp) ]. This SNP causes a reduced binding activity of TMC8 to TRADD (TNFRSF1A-associated via death domain) and leads to a less efficient apoptosis activation compared to the wild-type variant [29] . Its variant T was homozygously detected in a young HIV-positive patient with acquired EV, whereas the HIV-positive mother was found to be heterozygous for the SNP and to lack EV lesions [30] . Two sisters with classical EV but without nonsense or frameshift mutation in either of the TMC genes were also homozygous for the rarer SNP variant T [31] . Therefore, we hypothesized this SNP to influence the individual risk of cSCC development in combination with immunosuppression. In the non-EV population, little is known about the correlation of rs7208422, cSCC development and HPV infection. One study investigating this SNP in the general population reported a slightly increased odds ratio (1.7) for individuals with the homozygous T genotype compared to the homozygous A genotype [32] , a trend we could not confirm in RTRs. Our data do not support any significant influence of rs7208422 on the development of cSCC in the investigated RTR collective. Interestingly, among RTRs more than 82% of the cSCCs are HPV positive, which is in contrast to the gen- Data are expressed as numbers of SNPs with percentages in parentheses and used type of test. In case of 3 different genotypes, the p value was calculated by the Cochran-Armitage test (CATT) and logistic regression (lrpval). In case of only 2 different genotypes, the Fisher test (FT) was used. OR = Odds ratio, given with 95% confidence interval in parentheses; n.a. = not assessed.
eral population with an HPV DNA prevalence of only 27% in cSCC [33] . Furthermore, within a transplanted but cSCC-negative control group more than 60% of carriers of the homozygous variant A (rs7208422) or variant G (rs12452890) disclosed a significant association of seropositivity with β 2 -HPVs [34] . In compliance with our data, no association has recently been found between 11 specific TMC/EVER SNPs and cSCC development in RTRs and cardiac transplant recipients [34] . Of note, we have investigated 22 further TMC SNPs in our study, which do not show any significant correlation to cSCC development among RTRs either. This includes an SNP in TMC6 (rs12449858) which has been detected in a family with EV and was suggested to be correlated with EV development [35] .
Examination of a further SNP (rs1042522 in the TP53 gene), suggested to be involved in cSCC development [20] , showed no correlation with cSCC risk in RTRs, which is consistent with a single report [36] and a recently published meta-analysis [37] .
Our pilot study is limited by an unequal distribution of the male:female ratio as well as a missing HPV analysis of the cSCC. Additionally, it was impossible to evaluate the patients' ages at onset of the first cSCC because of missing data in the patient record. The presented survey examined few patients, but all of them had undergone renal transplantation. In correlation with other studies on transplanted patients, we could not detect any correlation between TMC/EVER SNPs and an increased risk of cSCC development. Possibly, an effect of TMC/EVER SNPs on cSCC development is hidden by other important influences, e.g. the type of HPV infection, age, sex or skin type. Combined studies on large cohorts of the general as well as the RTR population, investigating SNP genotype as well as HPV infection and cSCC status, might be necessary to detect a possible influence of TMC/EVER SNPs on HPV susceptibility and cSCC development.
